The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
In 2019, several large mergers and acquisitions (M&As) between pharmaceutical companies broke the billion-dollar mark. Engaging in transactions to broaden their pipelines and improve their profit-making capabilities, pharma businesses invested heavily in each other. This article lists the 10 biggest deals in terms of transaction size that were announced or completed last year.
BMS successfully acquired Celgene in November of last year, after it gained regulatory approval from all government authorities required.
Initially announced in January 2019, the agreement took 11 months until Celgene became a wholly owned subsidiary of BMS. The deal has widened the company’s pipelines in oncology, haematology, immunology and cardiovascular disease.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Commenting on the acquisition, Dr Giovanni Caforio, Chairman and Chief Executive Officer (CEO) of BMS, said: “This is an exciting day for BMS as we bring together the leading science, innovative medicines and incredible talent of BMS and Celgene to create a leading biopharma company.”
Since January 2019, several advancements to deliver on the key value drivers for the merger were undertaken, including progress relating to the patent estate for Revlimid.1
2. AbbVie/Allergan – $63 billion
In October 2019, Allergan shareholders voted to approve its acquisition by AbbVie, with over 99 percent of the votes in favour of the decision.
Announced in June, the M&A deal aims to produce new growth platforms and expand the revenue base for both companies.
“In addition to delivering value for shareholders, this combination will create a leading biopharmaceutical company with a diversified portfolio and enhanced opportunity to invest in and deliver innovation for the patients we serve,” said Brent Saunders, Chairman and CEO of Allergan.
The transaction is expected to close in early 2020, subject to customary closing conditions and regulatory approvals.2
3. Takeda Pharmaceutical Company (Takeda)/Shire – $58.6 billion
In January of last year, Takeda announced that it completed its M&A of Shire to expand its global biopharmaceutical capabilities headquartered in Japan.
According to Takeda, its R&D efforts are focused on oncology, gastroenterology, neuroscience and rare diseases, with investment into plasma-derived therapies and vaccines.
At the time, Christophe Weber, President and CEO of Takeda, said: “We are pleased to have completed the acquisition several months earlier than expected, which was enabled through the hard work of our respective organisations and the smooth receipt of regulatory clearances.
“This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicines.”3
4. Danaher Corporation/General Electric (GE) Biopharma – $21.4 billion
The agreement between Danaher and GE Biopharma was announced in February of last year to expand Danaher’s opportunities in the bioprocessing sector.
The M&A deal will add GE Biopharma’s instruments, consumables and software products to Danaher’s inventory in order to support its biopharmaceutical drug development.
Danaher’s President and CEO, Thomas Joyce, said: “GE Biopharma is renowned for providing best-in-class bioprocessing technologies and solutions.” He added that the acquisition would bring a “highly innovative, industry-leading product suite to our life sciences portfolio, providing an excellent complement to our current biologics workflow solutions.”4
In August 2019, Amgen announced that it had entered into an agreement with Celgene to acquire the rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis.
Amgen cited that the rights would accelerate the company’s short- and long-term revenue growth, especially due to its iexclusivity until at least 2028 in the US, as well as worldwide rights.
“Otezla represents an exciting opportunity to strengthen Amgen’s presence in inflammation and continue Amgen’s geographic expansion,” said Robert Bradway, Chairman and CEO at the company. “We are excited about the opportunity that Otezla represents for Amgen, for our shareholders and for patients worldwide.”5
6. Mylan/Upjohn (a division of Pfizer) – $12 billion
Mylan and Pfizer agreed to combine the former company with the latter’s subsidiary Upjohn in July of last year after a unanimous vote from the Board of Directors.
According to the companies, the transaction would accelerate the businesses’ ability to serve patient needs as well as bring Mylan’s portfolio into an alliance with Upjohn’s position in markets such as China.
The companies announced that they would be based in the US, but also operate global centres in China and India.
Robert Coury, Mylan Chairman, said: “The new company, which combines the unique assets of Mylan with the iconic brands of Pfizer’s Upjohn business, will not only accelerate our mission to serve the world’s changing health needs, but also further unlock the true value of our platform while delivering attractive returns to shareholders for many years to come.”6
7. Pfizer/Array Biopharma – $11.4 billion
The definitive merger between Pfizer and Array BioPharma was announced in June 2019 following the approval of the Board of Directors at both companies.
Array’s broad pipeline of targeted cancer medicines in development and its portfolio of potentially best- and first-in-class medicines are expected to expand Pfizer’s future revenue significantly.
“The acquisition of Array strengthens our innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory and sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer’s existing expertise in breast and prostate cancers,” said Albert Bourla, CEO of Pfizer.7
8. Novartis/The Medicines Company – $9.7 billion
In November 2019, Novartis announced that it had entered into an agreement and plan of merger with The Medicines Company.
According to Novartis, inclisiran, developed by The Medicines Company, represents a near-term product launch opportunity and is expected to contribute highly to revenues from 2021.
Novartis CEO, Vas Narasimhan, said: “We are excited about entering into an agreement to acquire The Medicines Company as inclisiran is a potentially transformational medicine that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolaemia… The prospect of bringing inclisiran to patients also fits with our overall strategy to transform Novartis into a focused medicines company.”
The M&A transaction is expected to close in the first quarter of 2020, subject to closing conditions.8
9. Eli Lilly and Company/Loxo Oncology – $8 billion
Eli Lilly and Loxo Oncology entered a definitive agreement for Lilly to acquire Loxo in July 2019, in order to broaden the first company’s cancer treatment options.
“Loxo Oncology’s portfolio of RET, BTK and TRK inhibitors targeted specifically to patients with mutations or fusions in these genes, in combination with advanced diagnostics that allow us to know exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer,” said Dr Daniel Skovronsky, Chief Scientific Officer (CSO) and President of Lilly Research Laboratories.
According to Lilly, the M&A will be the largest in a series of transactions it has completed to broaden its cancer treatment efforts.9
10. GlaxoSmithKline (GSK)/Tesaro – $5.1 billion
In January of last year, GSK successfully completed its acquisition of Tesaro, an oncology-focused company through its wholly owned subsidiary Adriatic Acquisition Corporation.
The agreement transferred Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor, currently approved for use in ovarian cancer, to GSK’s pipeline.
Dr Hal Barron, CSO and President, R&D, GSK, said: “The acquisition of Tesaro, which we have completed today, significantly strengthens our oncology pipeline and brings new scientific capabilities and expertise that will increase the pace and scale at which we can help patients living with cancer.”10
6. Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine | Pfizer [Internet]. Pfizer.com. 2020 [cited 22 January 2020]. Available from: https://www.pfizer.com/news/press-release/press-release…
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.